Acelyrin, Inc.

Acelyrin — Merger or Acquisition (February 2025)

18 slides from Acelyrin's merger presentation, Feb 6, 2025

  1. Slide 1: Alumis and ACELYRIN Merger Investor Presentation

    Transform Therapies. Reimagine Lives. February 6, 2025 Alumis and ACELYRIN Merger Investor Presentation |

  2. Slide 2: Disclaimer: Forward-Looking Statements

    Disclaimer Forward - Looking Statements This communication contains forward - looking statements within the meaning of federal securities laws, including the “safe harbor” provisions of th e Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and

  3. Slide 3: Creating Well Capitalized Company with Multiple Upcoming Development Milestones

    3 © Alumis Creating Well Capitalized Company with Multiple Upcoming Expected Development Milestones and Extended Runway into 2027 〉 Creates a late - stage clinical biopharma company dedicated to innovating, developing and commercializing transformative therapies for immune - mediated diseases 〉 Diff

  4. Slide 4: Transaction Highlights

    4 © Alumis 〉 All stock merger 〉 ACELYRIN stockholders to receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock owned Consideration 〉 Alumis stockholders to own ~ 55% of the combined company 〉 ACELYRIN stockholders to own ~ 45% of the combined company Pro Forma Ownershi

  5. Slide 5: Late-Stage Pipeline With Multiple Near-Term Catalysts

    Late - Stage Pipeline With Multiple Near - Term Catalysts 5 © Alumis 〉 Post transaction close, the company will consider development plan for lonigutamab in the context of the broader combined portfolio to drive long - term value for stockholders ANTICIPATED MILESTONES DEVELOPMENT PHASE 3 PHASE 2 PH

  6. Slide 6: Alumis Pipeline: Development Plan is on Track

    6 © Alumis Ongoing Phase 2b trial of ESK - 001 in systemic lupus erythematosus Phase 2 trial of A - 005 in multiple sclerosis A - 005 Ongoing Phase 3 trials of ESK - 001 in m oderate - to - severe plaque psoriasis Topline data readout expected in 1H 2026 Topline data readout expected in 2026 Initiat

  7. Slide 7: ACELYRIN's Lonigutamab: Next-Generation Subcutaneous Anti-IGF-1R Therapy

    ACELYRIN’s Lonigutamab A Next - Generation Subcutaneous Anti - IGF - 1R Therapy With Best - in - Class Potential in TED 7 Evaluating Lonigutamab Development Plan 〉 Lonigutamab is a unique asset given its mechanism of action and has best - in - class potential 〉 ACELYRIN plans to re - evaluate the de

  8. Slide 8: Flexibility and Runway to Advance Late-stage Therapies

    8 © Alumis F lexibility and Runway to Advance L ate - stage T herapies 〉 Standalone: Alumis and ACELYRIN had cash, cash equivalents and marketable securities of ~$289 million and ~$448 million, respectively, on a preliminary basis, as of December 31, 2024 〉 Combined Company: Pro forma cash of ~$737

  9. Slide 9: Recent Achievements and Anticipated Near-Term Milestones

    x x Recent Achievements and Anticipated Multiple Near - Term Milestones 2024 2025 2026 MAR24 APR24 JUL24 3Q24 YE24 ESK - 001 – Present Phase 2 STRIDE and OLE Data at AAD A - 005 – Phase 1 Initiation ESK - 001 – Initiate Phase 3 in PsO ESK - 001 – PsO OLE Data Update A - 005 – Phase 1 Data 1H26 2026

  10. Slide 10: Alumis/ACELYRIN Combination

    Alumis /ACELYRIN Combination © Alumis 10 Late - Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune - mediated Diseases Strong Portfolio, Large Opportunity 〉 Three potential best - in - class molecules: two advanced clinical TY

  11. Slide 11: Thank You!

    Thank You! % alumis

  12. Slide 12: Appendix

    Appendix % alumis

  13. Slide 13: Alumis: A Well Characterized Late-Stage Portfolio with Significant Opportunity

    13 Alumis: A Well Characterized Late - Stage Portfolio with Significant Opportunity Genomic, proteomic and clinical insights validate and drive our Research and Development strategy and increase the probability of technical success (PTS) of our programs Experienced team with strong track record of o

  14. Slide 14: TYK2 Is One Of The Most Attractive Targets In I&I

    〉 TYK2 pathway drives immune mediated diseases in the periphery and CNS via IL23, IL17 and IFN 〉 TYK2 inhibition interrupts the self - fueling inflammatory cycle by stopping the release of inflammatory mediators 〉 Oral therapy enables greater tissue penetration, convenience and potential for combina

  15. Slide 15: ESK-001 and A-005: A Highly Differentiated TYK2i Portfolio

    15 ESK - 001 and A - 005: A Highly Differentiated TYK2i Portfolio Phase 3 dose fully inhibits TYK2 by every measure in skin and blood* 〉 Maximal Target Inhibition Long term PASI and sPGA response rates competitive with high efficacy biologics 〉 High Response Oral No major safety signals to date with

  16. Slide 16: Maximal Target Inhibition Led to ~20% Increase in Clinical Response (PASI)

    © Alumis 16 Maximal Target Inhibition Led to 15 - 20% Increase in Clinical Response (PASI) Maximal Target Inhibition Maintained Across 24 - hour Dosing Period ( Phase 1 multidose trough PK) Clinical Outcomes at 28 Weeks (OLE Phase 2, PASI as observed) 1 10 100 1000 0 2 4 6 8 10 12 14 ESK - 001 Mean

  17. Slide 17: TYK2 Class has Extensive Validation with Substantial Market Potential

    TYK2 Class has Extensive Validation with Substantial Market Potential Across Immune - Mediated Diseases Ongoing trials: includes Alumis and other company clinical trials; Publicly disclosed indications for TYK2, Market size estimates for 2030 worldwide Biologic Rationale Genetic Evidence Ongoing Tri

  18. Slide 18: Lonigutamab – A Unique Mechanism for TED Patients

    © Alumis 18 Lonigutamab – A Unique Mechanism for TED Patients 〉 Robust subcutaneous efficacy in TED Patients comparable to SoC and investigational anti - IGF - 1R IV agents 〉 First clinical subcutaneous data in TED patients informs clinical development 〉 Optimized safety profile : potential for lowe

ACELYRIN — Merger or Acquisition (February 2025) on 6ix